Company

Kuhnil Pharmaceutical

As of the edition of 20 October 2026, Kuhnil Pharmaceutical runs 4 drugs; it is on route A at 3 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

Route A at 3 targets, route B at 0 targets.

Three of its 3 rows, by target and route
Target	Route
MTNR1A Melatonin receptor type 1A	Route A
MTNR1B Melatonin receptor type 1B	Route A
EGFR Epidermal growth factor receptor	Route A

In the product

3 company-target rows on route A or B; 0 are not shown here, and no score is.